The authors used a Markov model to compare two strategies for 45-55 year old Medicaid beneficiaries: (1) Current Practice鈥攐nly advanced disease is treated before Medicare eligibility; and (2) Full Access鈥攂oth early-stage and advanced disease are treated before Medicare eligibility. Full Access was less costly and more effective than Current Practice for all cohorts and perspectives, with differences in cost ranging from $5,369 to $11,960 and in effectiveness from 0.82 to 3.01 quality-adjusted life-years. Compared with Current Practice, Full Access averted 5,994 hepatocellular carcinoma cases and 121 liver transplants per 100,000 patients. 鈥淭wo recently approved interferon-free drug regimens for patients with hepatitis C genotype 1 disease鈥攕ofosbuvir/ledipasvir (or ombitasvir, paritaprevir) and ritonavir with dasabuvir鈥攁re more than 94% effective in as few as 8 weeks for many patient subgroups, but most state Medicaid programs restrict their use due to cost,鈥� said corresponding author Alexis P. Chidi, PhD, MSPH, of the , Pittsburgh, Pennsylvania. 鈥淎nd while such restrictive treatment policies are likely to reduce short-term costs to state Medicaid programs,鈥� she added, 鈥渙ur cost-effectiveness analysis revealed that for current Medicaid beneficiaries, the increased short-term costs of unrestricted access to care can be offset by savings from reduced complications in 9-16 years, depending on the treatment strategy and age of the cohort.鈥�
The authors noted several study limitations. First, analytic methods that directly account for resource constraints may provide more precise estimates. Second, the study estimated treatment efficacy using clinical trial data, which may overestimate real-word effectiveness. Third, some Medicaid managed care plans may receive smaller drug discounts than those mandated by the Medicaid drug rebate program. Finally, the model used in the study only included liver-related costs and did not account for the potential increases in cumulative health care costs associated with reduced early mortality.
###
ABOUT ISPORThe International Society for Pharmacoeconomics and Outcomes Research () is a nonprofit, international, educational and scientific organization that promotes health economics and outcomes research excellence to improve decision making for health globally. Web: www.ISPOR.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: http://bit.ly/ISPOR-T (@ISPORorg) | YouTube: http://bit.ly/ISPOR-YT |Facebook: http://bit.ly/ISPOR-FB
ABOUT VALUE IN HEALTH (ISSN 1098-3015) is an international, indexed journal that publishes original research and health policy articles that advance the field of pharmacoeconomics and outcomes research to help health care leaders make evidence-based decisions. The journal鈥檚 2015 impact factor score is 3.824. Value in Health is ranked 3rd out of 74 journals in health policy and services (social sciences), 8th out of 87 journals in health care sciences and services, and 10th out of 344 journals in economics (social sciences). Value in Health is published bi-monthly and circulates to more than 10,000 readers around the world. Web: | Twitter: (@ISPORjournals)
RSS